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Hypocholesterolemia:  
Α Blessing or a Problem?
Athanasios G. Yalouris, MD
We are all accustomed to face serum cholesterol as a potential threat for our 
health and so wish and try to have its levels as low as possible. So, in clinical practice 
we are rather indifferent or even satisfied when we find very low serum cholesterol 
levels -what we can call “hypocholesterolemia- in a certain individual. Is this practice 
right or it should be reevaluated? Since cholesterol is an important component of all 
cell membranes and its concentrations affect membrane permeability and fluidity it is 
highly probable that very low levels of it may disturb some cell functions and participate 
in the pathogenesis of diseases.
Let’s start with a definition of the term, although this is not generally accepted. 
It can be described as a serum total cholesterol level under the fifth percentile of a 
general population adjusted for sex and age.1 In a less complicated manner it can be 
defined as less than 115 mg/dl. In a study of 7,000 healthy blood donors, a percentage 
of 7.8% were found to meet the criteria for hypocholesterolemia. 
Hypocholesterolemia may be congenital or acquired. Congenital conditions are 
either combined with low LDL- (low density lipoprotein) or low HDL- (high density 
lipoprotein) cholesterol levels.
1. Hypocholesterolemia with low LDL-cholesterol: it is due to a deficiency of 
apoprotein B, (apo-B), the main protein component of LDL. It can appear in: 
 i. Abetalipoproteinemia: this is a rare, autosomal recessive disorder characterized by 
a deficiency of microsomal triglyceride transfer protein. The result is malabsorp-
tion of fat and fat-soluble vitamins. It presents in the first few months of life with 
defective growth and steatorrhea. If untreated, it progresses to serious neurologic 
manifestations (ataxia, peripheral neuropathy, retinal degeneration) due to de-
generation of the spinocerebellar and dorsal columns tracts.2 
 ii. Familial hypobetalipoproteinemia: this a rare autosomal codominant disorder. Its 
homozygous type is accompanied with severe fat malabsorption with consequences 
similar to the other here-described disorders. The heterozygous form is less rare 
(1:500 subjects) and is usually asymptomatic.3
 iii. Chylomicron retention disease: this is a rare autosomal recessive disorder resulting 
in decreased intestinal absorption of triglycerides, cholesterol, and lipid-soluble 
vitamins. Clinical symptoms present in infancy or early childhood with slow growth 
and steatorrhea. Hepatic steatosis, neurologic disorders and amyotrophy can de-
velop later in childhood.4
2. Hypocholesterolemia with low HDL-cholesterol: it is caused by a deficiency of 
apoprotein A, (apo-A), the main protein component of HDL. It can appear in: 
 i. Tangier disease: this is a rare autosomal recessive disorder characterized by a 
deficiency of ATP-binding cassette transporter, a protein that orients cellular 
cholesterol towards the cell surface and facilitates its transfer towards the core 
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of HDL. As a result, cholesterol cannot be incorporated 
in the molecule of HDL and it is accumulated in several 
tissues, as peripheral nerves, dorsal roots, liver, spleen, 
tonsils, lymph nodes, cornea and intestinal mucosa. The 
clinical manifestations include neuropathy, hepatomegaly, 
splenomegaly, enlarged, orange-colored tonsils, corneal 
clouding, diabetes mellitus and increased risk of athero-
sclerosis.5
 ii. Familial hypoalphalipoproteinemia: this is a rare auto-
somal dominant disorder caused by various deletions and 
mutations resulting in either decreased apo A-I production 
or function or increased apo A-I catabolism. Plasma HDL 
cholesterol concentrations are very low. Some patients 
may remain asymptomatic but in others may appear from 
adolescence corneal opacities or cataract, xanthomas or 
xanthelasmas and premature atherosclerosis. Neurologic 
symptoms (cerebellar ataxia, neurosensory hearing loss, 
proliferative retinopathy) or secondary amyloidosis leading 
to liver, renal or cardiac failure have also been described.6
 iii. LCAT deficiency: this is a very uncommon autosomal 
recessive disorder. Lecithin-cholesterol acyl transferase 
(LCAT) is an enzyme that catalyzes esterification of free 
cholesterol in lipoprotein molecules. Its deficiency results 
to accumulation of free cholesterol in several tissues. Clini-
cal manifestations include corneal opacities, anemia, renal 
failure and accelerated atherosclerosis.7
Acquired causes of hypocholesterolemia include:
 1. Hyperproliferative anemias (e.g. hemolytic): increased 
erythropoiesis results in cholesterol consumption.
 2. Hyperthyroidism: it is caused by increased expression of 
LDL-cholesterol receptors.
 3. Liver failure: it is due to decreased synthesis of cholesterol 
esters.
 4. Malabsorption syndromes
 5. Malnutrition
 6. Chronic infections, such as tuberculosis, chronic hepatitis, 
AIDS: hypocholesterolemia is probably caused by the ac-
tion of cytokines. Its presence was found to be combined 
with lower levels of CD4 and CD8 lymphocytes, smaller 
thymus volume and increased ratio of antiretroic treatment 
failure.8
 7. Drugs, including statins and several hypolipidemic 
substances. Recommended serum cholesterol levels for 
secondary prevention of cardiovascular diseases often 
are within the limits of hypocholesterolemia. Whether 
this represents or not an abnormal condition should be 
discussed. Of course, there are several clinical studies of 
long-term evaluation of patients under intensive statin 
treatment claiming that it is safe, e.g. the JUPITER study 
for primary9 or the SATURN study for secondary pre-
vention.10 However, a clinical doctor must always have in 
mind that all biological parameters are usually fluctuating 
between a higher and a lower normal level and any devia-
tion from them may have undesired consequences, either 
acute or delayed. Furthermore, one must not ignore some 
rather heretic studies, especially metanalyses, supporting 
that although cardiovascular mortality was significantly 
reduced after hypocholesterolemic treatment for primary 
prevention, the all-cause mortality remained unchanged. 
This finding obviously indicates that this treatment caused 
an increase of non-cardiovascular mortality.11,12
Hypocholesterolemia has often been related to several 
abnormal conditions. However, in most cases the existing data 
are rather conflicting.
1. Malignant diseases: Several studies have shown a 
decreased level of serum cholesterol (often at levels of hypo-
cholesterolemia) in well-nourished patients with solid tumors 
(e.g. lungs, gastrointestinal tract) or hematologic malignan-
cies.13 It is not clear whether hypocholesterolemia participates 
in the pathogenesis of the malignancy or it is caused by it. 
In the SEAS study, combined administration of simvastatin 
and ezetimibe was accompanied with a significant (p<0.01) 
increase in cancer cases but it is not clear whether it should 
be attributed to the hypocholesterolemia or the action of the 
drugs.14 A prospective study with a follow-up of 7735 individu-
als aged 40-59 for a median of 14.8 years showed an increased 
mortality due to cancer in patients with hypocholesterolemia. 
However, this effect was most pronounced in the first five 
years and became attenuated and non-significant with longer 
follow-up.15 This may be an indication that some patients 
already had a preclinical malignancy during the beginning of 
the study and so hypocholesterolemia was a manifestation of 
the disease and not a factor contributing to it.
2. Mental disorders: There are numerous studies -mainly 
from psychiatric units- relating low serum cholesterol with 
depression and suicidality16,17 and some with other psychiatric 
disorders, like schizophrenia18 or antisocial personality.19 A 
considerable number of them is based on a small number of pa-
tients or has several methodological problems.20 Furthermore, 
there are some other studies that deny this effect.21 In a large 
retrospective study, men with serum cholesterol values less 
than 160 mg/dl had a significantly higher ratio of deaths due to 
suicide.22 The involvement of cholesterol in affective disorders 
remains a debated issue in current research but the results are 
controversial. On the contrary, the majority of literature shows 
a more consistent relationship between cholesterol levels and 
suicidality, with few studies that have found no relationships.23 
Concerning the possible mechanisms, one must keep in mind 
that cholesterol is an important component of cell plasma 
membrane. Due to its chemical composition it fits into the 
lipid bilayer and has a condensing effect on the packing of 
lipids. Its presence in cell membranes is involved with signal-
ing in diverse cellular processes, such as immune regulation, 
cell cycle control, membrane trafficking and fusion events. 
Several recent studies have linked many of these functions 
with the effects of membrane cholesterol content.24 Among 
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these functions is probably the regulation of serotonin reup-
take in neurons, a procedure that is of main importance in the 
pathogenesis of mental disorders. Of course, such a link is not 
easy to be studied in humans. One animal study showed that 
lowering cholesterol levels resulted in lower central nervous 
system serotonergic activity and higher levels of aggression.25 
An additional point of view is that hypocholesterolemia may 
be sometimes associated with low levels of polyunsaturated 
fatty acids which are also implicated in the pathogenesis of 
several psychiatric disorders.26 
3. Hemorrhagic stroke: Several studies have shown a sta-
tistically significant inverse association between serum total or 
LDL-cholesterol concentrations and the risk of hemorrhagic 
stroke. An increment of 1 mmol/l (39 mg/dl) in total choles-
terol was associated with a 15% decreased risk of hemorrhagic 
stroke.27 We must, however emphasize that in patients receiv-
ing hypolipidemic treatments, this risk is counterbalanced by 
the reduction of ischemic stroke cases.
4. Critically ill patients: There are considerable data 
indicating that in critically ill patients -such as with serious 
polytrauma, extensive surgery, sepsis or protracted hypov-
olemic shock- serum cholesterol levels are decreased and their 
levels may serve as a prognostic factor. In a study of critically 
ill trauma patients, mean cholesterol levels were significantly 
low (119 ± 44 mg/dl) and in those who died, they finally fell 
by 33% while on the contrary they had a 28% increase in sur-
vivors.28 The underlying mechanisms of hypocholesterolemia 
in these patients are obscure. It is not clear whether the main 
disease causes hypocholesterolemia or hypocholesterolemia 
actively contributes to its deterioration. Both possibilities have 
been suggested. Proinflammatory cytokines may decrease cho-
lesterol synthesis. On the other hand, since lipoproteins can 
bind and neutralize bacterial lipopolysaccharides, it is prob-
able that cholesterol has a role in the inflammatory response 
against Gram-negative bacteria and its decreased presence 
may contribute to the deterioration of some infections.1 New 
therapies directed at increasing low cholesterol levels are under 
consideration for the treatment of sepsis.
5. Elderly people: In a considerable number of elderly 
people serum cholesterol falls significantly with increasing age. 
However, many elderly people continue to receive hypocho-
lesterolemic treatment for primary or secondary prevention 
of cardiovascular diseases. In a study of 724 individuals, aged 
85 years and over, followed for 10 years it was found that 
mortality was higher in groups of lower serum cholesterol 
concentrations, mainly from cancer and infection. The authors 
concluded that each 1 mmol/l (39 mg/dl) increase in total 
cholesterol corresponded to a 15% decrease in mortality.30 A 
study of 3572 men aged 71–93 years who were followed for 
over 20 years showed that relative risks for mortality were 
significantly lower in the second, third, and fourth quartiles of 
serum cholesterol as compared to the first (lowest) quartile. No 
significant difference of mortality was observed among these 
three groups. Such data cast doubt on the scientific justifica-
tion for lowering cholesterol to very low concentrations (less 
than 180 mg/dl) in elderly people.31
In conclusion, hypocholesterolemia is an existing entity 
and clinical doctors should be familiar to it. If presenting in 
early life it may be due to several uncommon genetic disor-
ders. Its appearance in adult life should be investigated as a 
secondary manifestation of an underlying disease. People with 
low serum cholesterol levels -either preexisting or caused by 
intensive hypocholesterolemic therapy- are exposed to pos-
sible health risks. A clinical doctor must have in mind that 
hypocholesterolemia may sometimes be equally harming to 
hypercholesterolemia. So, by adjusting all the existing data 
about his patients must at any case individualize his therapeutic 
interventions, trying to find the optimal levels of cholesterol 
than going towards either end of the cholesterol scale.29
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